(Reuters) – BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.
The drugmaker said the results of its early-to-mid stage study testing the therapy did not meet the threshold to warrant additional capital investment.
(Reporting by Puyaan Singh; Editing by Shinjini Ganguli)
Comments